UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

2014 Epilepsy Benchmarks Area III: Improve Treatment Options for Controlling Seizures and Epilepsy-Related Conditions Without Side Effects

Dlugos, D; Worrell, G; Davis, K; Stacey, W; Szaflarski, J; Kanner, A; Sunderam, S; ... Dingledine, R; + view all (2016) 2014 Epilepsy Benchmarks Area III: Improve Treatment Options for Controlling Seizures and Epilepsy-Related Conditions Without Side Effects. Epilepsy Currents , 16 (3) pp. 192-197. 10.5698/1535-7511-16.3.192. Green open access

[thumbnail of 1535-7511-16%2E3%2E192.pdf]
Preview
Text
1535-7511-16%2E3%2E192.pdf - Published Version

Download (287kB) | Preview

Abstract

The Epilepsy Benchmark goals in Area III focus on making progress in understanding and controlling seizures and related conditions as well as on developing biomarkers and new therapies that will reduce seizures and improve outcomes for individuals with epilepsy. Area III emphasizes a need to better understand the ways in which seizures start, propagate, and terminate and whether those network processes are common or unique in different forms of epilepsy. The application of that knowledge to improved seizure prediction and detection will also play a role in improving patient outcomes. Animal models of treatment-resistant epilepsy that are aligned with etiologies and clinical features of human epilepsies are especially encouraged as necessary tools to understand mechanisms and test potential therapies. Antiseizure therapies that target (either alone or in combination) novel or multiple seizure mechanisms are prioritized in this section of the Benchmarks. Area III goals also highlight validation of biomarkers of treatment response and safety risk, effective self-management, and patient-centered outcome measures as important areas of emphasis for the next five to ten years.

Type: Article
Title: 2014 Epilepsy Benchmarks Area III: Improve Treatment Options for Controlling Seizures and Epilepsy-Related Conditions Without Side Effects
Open access status: An open access version is available from UCL Discovery
DOI: 10.5698/1535-7511-16.3.192
Publisher version: http://dx.doi.org/10.5698/1535-7511-16.3.192
Language: English
Additional information: Epilepsy Currents by American Epilepsy Society is licensed under a Creative Commons Attribution 3.0 Unported License.
Keywords: Science & Technology, Life Sciences & Biomedicine, Clinical Neurology, Neurosciences & Neurology, Temporal-Lobe Epilepsy, Focal Cortical Dysplasia, Targeted Responsive Neurostimulation, Refractory Partial Seizures, Intractable Epilepsy, Ezogabine Retigabine, Long-Term, Somatic Mutations, Mammalian Target, Controlled-Trial
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology > Clinical and Experimental Epilepsy
URI: https://discovery.ucl.ac.uk/id/eprint/1502687
Downloads since deposit
96Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item